Category: Retinal diseases

In the United States, approximately 20 million people have some form of age-related macular degeneration (AMD), and about 200,000 new cases of wet AMD are diagnosed annually [1.10.2]. While anti-VEGF therapy has been a revolutionary treatment, researchers are actively exploring alternatives to reduce treatment burden. So, what is the alternative to anti-VEGF?

Originally approved for cancer treatment, Avastin (bevacizumab) has revolutionized ophthalmology as a widely used 'off-label' medication. When administered as an intraocular injection, **what is the use of Avastin in eye disease** is primarily to halt the growth of abnormal blood vessels that cause vision loss in various retinal conditions.